基于单核苷酸多态性产前无创DNA筛查异常结果提示母体恶性肿瘤
本回顾性队列研究分析2015年1月至2021年10月商业实验室的SNP无创产前筛查样本,共2,004,428例,其中38例(0.002%,约1/52,748)SNP图提示母体恶性肿瘤。获随访的30例中20例(66.7%)确诊或疑似恶性肿瘤,最常见为淋巴瘤、乳腺癌和结肠癌。作者建议对所有此类结果的孕妇进行恶性肿瘤排查。
要点
- SNP无创产前筛查提示母体恶性肿瘤罕见,约1/52,748(95%CI 1:74,539-1:38,430)。
- 获临床随访的30例中20例(66.7%)确诊或疑似恶性肿瘤。
- 最常见恶性肿瘤为淋巴瘤(n=10)、乳腺癌(n=5)、结肠癌(n=3)。
核心结论
- SNP无创产前筛查提示母体恶性肿瘤罕见(约1/53,000),但本研究中三分之二获随访患者有癌症诊断。
- 作者建议对所有此类结果的孕妇进行恶性肿瘤排查。
研究设计与样本
- 回顾性队列研究,纳入2015年1月至2021年10月商业实验室的SNP无创产前筛查样本,共2,004,428例。
- 通过电话、传真或电子邮件联系转诊临床医生办公室获取临床随访。
主要发现
- 38例样本(0.002%,约1/52,748,95%CI 1:74,539-1:38,430)SNP图提示母体恶性肿瘤。
- 30例(78.9%)获得母体健康结局,8例失访。
- 30例获随访患者中20例(66.7%)确诊或疑似恶性肿瘤。
- 最常见恶性肿瘤为淋巴瘤(n=10)、乳腺癌(n=5)、结肠癌(n=3)。
临床怎么用
- 作者建议对所有SNP无创产前筛查结果提示母体恶性肿瘤的孕妇进行恶性肿瘤排查。
局限性
- 本研究为回顾性队列研究。
- 38例中仅30例(78.9%)获得临床随访,8例失访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the incidence and clinical outcomes of cell-free DNA results suspicious for maternal malignancy on prenatal cell-free DNA screening with single-nucleotide polymorphism (SNP)-based technology. METHODS: This retrospective cohort study included data from SNP-based, noninvasive prenatal screening samples from a commercial laboratory from January 2015 to October 2021. Maternal plasma was screened for trisomy 21, 18, and 13; monosomy X; and triploidy. Cases were considered suspicious for maternal malignancy if retrospective bioinformatics and visual inspection of the SNP plot were suggestive of multiple maternal copy number variants across at least two of the tested chromosomes. Clinical follow-up on patients was obtained by contacting individual referring clinician offices by telephone, facsimile, or email. RESULTS: A total of 2,004,428 noninvasive prenatal screening samples during the study period met criteria for inclusion in the analysis. Of these, 38 samples (0.002% or 1 in 52,748, 95% CI 1:74,539-1:38,430) had SNP-plot results that were suspicious for maternal malignancy. Maternal health outcomes were obtained in 30 of these patients (78.9%); eight were lost to follow-up. Maternal malignancy or suspected malignancy was identified in 66.7% (20/30) of the 30 patients with clinical follow-up provided by the clinic. The most common maternal malignancies were lymphoma (n=10), breast cancer (n=5), and colon cancer (n=3). CONCLUSION: Results suspicious for maternal malignancy are rare with SNP-based noninvasive prenatal screening (1:53,000), but two thirds of patients who had a noninvasive prenatal screening result concerning for malignancy in this study had a cancer diagnosis. Investigation for malignancy should be recommended for all pregnant patients with this type of result. FUNDING SOURCE: This study was funded by Natera, Inc.
引用
- Goldring G, Trotter C, Meltzer JT, et al. Maternal Malignancy After Atypical Findings on Single-Nucleotide Polymorphism-Based Prenatal Cell-Free DNA Screening. Obstet Gynecol. 2023. PMID: 36897127. doi:10.1097/AOG.0000000000005107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。